Advisors Asset Management Inc. trimmed its stake in Regeneron Pharmaceuticals by 7.9%, selling 443 shares in the fourth ...

Regeneron Pharmaceuticals saw a shakeup as iA Global Asset Management trimmed its holdings by 11.7%, selling off 1,538 shares ...

Shares of Regeneron Pharmaceuticals Inc. REGN shed 1.45% to $662.62 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.22% ...

Regeneron Pharmaceuticals Inc. closed 44.49% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors�reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

"What we are trying to do is put you out of business and bankrupt you,” said conservative strategist Steve Bannon.

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

Laurence has held several executive positions within the industry, serving as CEO at Decibel Therapeutics (acquired by Regeneron Pharmaceuticals) and Warp Drive Bio (merged with Revolution Medicines), ...

NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other oversold blue chip stocks. The uncertainty related to the tariff ...